BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 31, 2002
View Archived Issues
Inspire Says INS365 NDA Filing Not Far Off; Stock Jumps 53%
Inspire Pharmaceuticals Inc. said following a productive meeting with the FDA, it has decided to compile existing data from three trials of its dry-eye product, INS365 Ophthalmic, and submit it for regulatory approval. (BioWorld Today)
Read More
Patience Is Secret Of Herpes Virus Long-Term Latency Strategy, Not Molecular Maneuverings In People
Read More
Neurogenetics Closes Series B With Second Tranche Of $10M
Read More
Other News To Note
Read More
Correction
Read More
Serono, IVAX Sign To Develop Cladribine As Oral MS Treatment
Read More
U.S. Patent Disclosures
Read More
Kemia Closes Potential $16.5M Series A To Fund Clinical Trials
Read More